Nuvation Bio Q1 2023 net loss $21.7M; cash $646.6M; DDC IND on track for year-end

Nuvation Bio Inc.

2023-Q1 EPS reported -$0.10

Net loss of $21.7M ($0.10 per share) vs $21.3M ($0.10) in Q1 2022.
Cash, cash equivalents and marketable securities of $646.6M as of March 31, 2023.
R&D expenses decreased to $18.8M from $20.7M, primarily due to headcount reduction and NUV-422 program termination.
Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy study both enrolling.
IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvation Bio Inc. reported the first quarter ended March 31, 2023 results: net income $21.7 million, EPS $(0.10) per share.

Period: the first quarter ended March 31, 2023
Net income: $21.7 million
EPS: $(0.10) per share
Result: reported results

Exact text from the filing

For the three months ended March 31, 2023, Nuvation Bio reported a net loss of $21.7 million, or $(0.10) per share.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-135935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.